Stage III NSCLC: Practical Application of Immune Checkpoint Inhibition After Chemoradiotherapy
The goal of this activity is to improve participants’ knowledge of and competence in applying immune checkpoint inhibitors in the treatment of patients with stage III NSCLC.
This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with stage III non-small-cell lung cancer.
Upon completion of this activity, participants should be able to:
- Discuss the biologic rationale for using immune checkpoint inhibitors in patients with locally advanced NSCLC.
- Plan optimal, individualized therapeutic strategies for patients with stage III NSCLC, considering the available clinical evidence, expert recommendations, and patient preferences.
- Identify subsets of patients most likely to benefit from durvalumab consolidation after definitive platinum-based chemotherapy and concurrent radiation therapy.
- Assess and manage immune-mediated adverse events experienced by patients receiving immune checkpoint inhibitors.
- Explain the benefits and risks of using immune checkpoint inhibitor therapy to patients with unresectable stage III NSCLC.
Matthew Gubens, MD, MS
Associate Professor Thoracic Oncology
University of California, San Francisco
San Francisco, California
Leora Horn, MD, MSc, FRCPC
Associate Professor of Medicine
Clinical Director, Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt Ingram Cancer Center
Karen L. Reckamp, MD, MS
Professor Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of National Comprehensive Cancer Network (NCCN) and Clinical Care Options, LLC. NCCN is accredited by the ACCME to provide continuing medical education for physicians.
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category 1 credit for completing this activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: 0836-9999-18-031-L01-P
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation